2 stories mentioning SHA:600161Updated 53m ago
Every FINWIRES story that references SHA:600161, newest first.
China's drug regulator granted Beijing Tiantan Biological Products (SHA:600161) subsidiary Chengdu Rongsheng Pharmaceutical supplemental approval for its recombinant human coagulation factor VIII for injection, according to a Tuesday filing with the Shanghai bourse.The product which is a blood clotting protein, is subject to good manufacturing practice compliance, according to the filing.
Beijing Tiantan Biological Products (SHA:600161) received a drug registration certificate from China's National Medical Products Administration for its human immunoglobulin injection, according to a Shanghai bourse filing on Tuesday.The injection is used for the treatment of primary immunodeficiency diseases in patients aged 2 years and older, including X-linked agammaglobulinemia, common variable immunodeficiency and IgG subclass deficiency.The blood products manufacturer invested 104.5 million yuan into the research and development of the drug.
